Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jun 26, 2026, 5:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 111 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacology, Clinical Clear all
Completed Early Phase 1 Interventional

Pharmacologic and Clinical Testing of a D1 Agonist for Cognitive Enhancement in Neuropsychiatric Disorders

NCT01519557
View directory record Official record
Conditions
Schizophrenia, Schizoaffective Disorder
Interventions
DAR-100A, Placebo
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 3, 2015 · Synced Jun 26, 2026, 5:30 AM EDT
Terminated Phase 3 Interventional Results available

WAveCrest Vs. Watchman TranssEptal LAA Closure to REduce AF-Mediated STroke 2

NCT03302494
View directory record Official record
Conditions
Stroke
Interventions
Coherex WaveCrest® Left Atrial Appendage Occlusion System, Watchman® LAA Closure Device
Device
Lead sponsor
Coherex Medical
Industry
Eligibility
18 Years and older
Enrollment
248 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
23
States / cities
Birmingham, Alabama • Chandler, Arizona • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 1Phase 2 Interventional

Chemotherapy in Treating Patients With Breast Cancer

NCT00012129
View directory record Official record
Conditions
Breast Cancer
Interventions
liposomal annamycin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 10, 2016 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Characterizing Clinical and Pharmacological Neuroimaging Biomarkers

NCT03842800
View directory record Official record
Conditions
Cognitive Impairment
Interventions
MRI, Ketamine
Other · Drug
Lead sponsor
Yale University
Other
Eligibility
16 Years to 60 Years
Enrollment
143 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 30, 2020 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Role of P-glycoprotein in Sitagliptin Clinical Pharmacology

NCT01112670
View directory record Official record
Conditions
Healthy
Interventions
Sitagliptin, atorvastatin
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
21 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 23, 2013 · Synced Jun 26, 2026, 5:30 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Understanding the Clinical Pharmacology of Marijuana-Tobacco Co-administration

NCT05999383
View directory record Official record
Conditions
THC, Cannabis, Cannabis Use, Cannabis Smoking, Tobacco Use, Vaping
Interventions
Cannabis, Nicotine, Pax Loose Leaf Vaporizer, Placebo Marijuana
Drug · Device · Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2026 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of Safety and Efficacy of Lumason/SonoVue in Subjects Undergoing Pharmacologic Stress BR1-141

NCT02522481
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Lumason
Drug
Lead sponsor
Bracco Diagnostics, Inc
Industry
Eligibility
18 Years and older
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
10
States / cities
Tucson, Arizona • La Jolla, California • West Hills, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2021 · Synced Jun 26, 2026, 5:30 AM EDT
Recruiting No phase listed Observational

A Natural History Study Seeks to Understand the Clinical, Genomic, Pharmacological, Laboratory, and Dietary Determinates of Pyrimidine and Purine Metabolism Disorders

NCT06092346
View directory record Official record
Conditions
AMPD3, OMIM*102772, AMP Deaminase Deficiency, AK1, OMIM *103000, Adenylate Kinase Deficiency, AMPD1, OMIM *102770, Myopathy Due to Myoadenylate Deaminase Deficiency, TPMT, OMIM *187680, Thoipurines, Poor Metabolism of, IMPDH1, OMIM *146690, Retinitis Pigmentosa Type 10, Leber Congenital Amauriosis Type 11, APRT, OMIM *102600, Adenine Phosphoribosyltransferase Deficiency, HPRT1, OMIM *308000 Lesch-Nyhan Disease, XDH, OMIM *607633, Xanthinuria Type 1, SLC2A9, OMIM *606142 Hypouricemia, SLC22A12, OMIM *607096 Hypouricemia, PRPS1 Def, OMIM *311850, Arts Syndrome; Charcot-Marie-Tooth Disease, PRPS1 SA, OMIM *311850 Gout, PRPS-related Phosphoribosylpyrophosphate Synthetase Superactivity, AMPD2, OMIM *102771, Spastic Paraplegia 63; Pontocerebellar Hypoplasia, ITPA, OMIM *147520, Inosine Triphosphatase Deficiency; Developmental and Epileptic Encephalopathy 35, ADSL, OMIM *608222, Adenylosuccinate Lyase Deficiency, PNP, OMIM *164050, Nucleoside Phosphorylase Deficiency, ADA2, OMIM *607575,Sneddon Syndrome; VAIHS, CAD, *1140120, Developmental and Epileptic Encephalopathy, UPB1, OMIM *606673, Beta-ureidopropionase Deficiency, DPYS, OMIM *613326, Dihydropyrimidinase Deficiency, DPYD, OMIM *274270, Dihydropyrimidine Dehydrogenase Deficiency, DHODH, OMIM *126064, Miller Syndrome (Postaxial Acrofacial Dysostosis), UMPS, OMIM *613891, Orotic Aciduria, NT5C3A<TAB>, OMIM *606224, Anemia, Hemolytic, Due to UMPH1 Deficiency, UNG, OMIM *191525, Hyper-IgM Syndrome 5, AICDA, OMIM *605257, Immunodeficiency With Hyper-IgM, Type 2; HIGM2, Purine-Pyrimidine Metabolism, Metabolic Disease
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
1 Month to 100 Years
Enrollment
999 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2099
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Clinical Performance, Safety and Pharmacology Effect of EscharEx in Patients With Lower Leg Ulcers

NCT04817228
View directory record Official record
Conditions
Venous Leg Ulcer, Diabetic Foot Ulcer
Interventions
EscharEx (EX-02 formulation)
Drug
Lead sponsor
MediWound Ltd
Industry
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Tamarac, Florida • Las Vegas, Nevada • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 25, 2022 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of AG-120 (Ivosidenib) in Subjects With Mild or Moderate Hepatic Impairment or Normal Hepatic Function

NCT03282513
View directory record Official record
Conditions
Hepatic Impairment
Interventions
AG-120 (Ivosidenib)
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
2
States / cities
Lakewood, Colorado • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Jun 26, 2026, 5:30 AM EDT
Terminated Phase 1 Interventional

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours

NCT04949425
View directory record Official record
Conditions
Advanced Solid Tumours
Interventions
Adavosertib
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Jun 26, 2026, 5:30 AM EDT
Completed No phase listed Observational

The Treatment of Children and Adolescents With Treatment-Resistant Depression

NCT00029640
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Not listed
Lead sponsor
National Institute of Mental Health (NIMH)
NIH
Eligibility
Not listed
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Jun 26, 2026, 5:30 AM EDT
Terminated Phase 1 Interventional

Cardiovascular Safety Study of Tipifarnib in Patients With Advanced Solid Malignancies

NCT04865159
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
Tipifarnib
Drug
Lead sponsor
Kura Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
3
States / cities
Canton, Ohio • Austin, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic Study of Alpelisib in Subjects With Hepatic Impairment.

NCT02624557
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Alpelisib
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
4
States / cities
Lakewood, Colorado • Miami, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Jun 26, 2026, 5:30 AM EDT
Recruiting Phase 3 Interventional

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

NCT07555483
View directory record Official record
Conditions
Alpha 1 Antitrypsin Deficiency
Interventions
Alpha-1 15%, Liquid Alpha1-PI
Drug · Other
Lead sponsor
Grifols Therapeutics LLC
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
10
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated May 31, 2026 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ABT-384 in Elderly Subjects

NCT00968422
View directory record Official record
Conditions
Healthy
Interventions
ABT-384, Matching placebo to ABT-384
Drug
Lead sponsor
Abbott
Industry
Eligibility
65 Years and older
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2009
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 2, 2010 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Clinical Pharmacology of Electronic Cigarettes

NCT02470754
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Tobacco Cigarette, Electronic Cigarette
Device
Lead sponsor
University of California, San Francisco
Other
Eligibility
21 Years and older
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Jun 26, 2026, 5:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

NCT04198766
View directory record Official record
Conditions
Solid Tumor, Non-Small Cell Lung Cancer, Head and Neck Cancer, Melanoma, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
Interventions
INBRX-106 - Hexavalent OX40 agonist antibody, pembrolizumab 200 mg, pembrolizumab 400 mg, Carboplatin AUC-5, Carboplatin AUC-6, Pemetrexed 500 mg/m2, Cisplatin 75mg/m2, Paclitaxel 200mg/m2, Nab paclitaxel 100mg/m2
Drug
Lead sponsor
Inhibrx Biosciences, Inc
Industry
Eligibility
18 Years and older
Enrollment
296 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
30
States / cities
Duarte, California • Glendale, California • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2025 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

Clinical Efficacy of Tranexamic Acid and ε-Aminocaproic Acid in Reducing Blood Loss Following Total Knee Replacement

NCT01873768
View directory record Official record
Conditions
Osteoarthritis
Interventions
Tranexamic Acid (TXA), ε-Aminocaproic Acid (EACA)
Drug
Lead sponsor
Miller Orthopedic Specialists
Other
Eligibility
18 Years to 90 Years
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Council Bluffs, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 20, 2016 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional

Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer

NCT00134069
View directory record Official record
Conditions
Recurrent Colon Cancer, Recurrent Rectal Cancer, Stage III Colon Cancer, Stage III Rectal Cancer, Stage IV Colon Cancer, Stage IV Rectal Cancer
Interventions
sorafenib tosylate, cetuximab, irinotecan hydrochloride
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
2
States / cities
Aurora, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 15, 2014 · Synced Jun 26, 2026, 5:30 AM EDT
Terminated Phase 4 Interventional Results available

Clinical, Pharmacological and Molecular Effects of IV and Oral Acetaminophen in Adults With aSAH

NCT02549716
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Stroke
Interventions
IV acetaminophen, Oral acetaminophen, Oral placebo, IV placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 9, 2019 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Bioavailability of a Single Oral Dose of the Acetylsalicylic Acid Containing Dry Powder 500 mg in Comparison to the Bioavailability of a Single Oral Dose of Aspirin Tablets and Aspirin Effervescent Tablets in Healthy Adults.

NCT02394093
View directory record Official record
Conditions
Pharmacology, Clinical
Interventions
Aspirin (Acetylsalicylic acid, BAYe4465)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 55 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 18, 2016 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 2 Interventional Results available

Sirolimus in Treating Patients With Advanced Pancreatic Cancer

NCT00499486
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
sirolimus
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 18, 2016 · Synced Jun 26, 2026, 5:30 AM EDT
Completed Phase 4 Interventional

Effectiveness Study of Single Photon Emission Computed Tomography (SPECT) Versus Positron Emission Tomography (PET) Myocardial Perfusion Imaging

NCT00976053
View directory record Official record
Conditions
Coronary Artery Disease
Interventions
Myocardial perfusion imaging
Procedure
Lead sponsor
Aspire Foundation
Other
Eligibility
30 Years to 90 Years
Enrollment
330 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2014 · Synced Jun 26, 2026, 5:30 AM EDT